Brind.

Oxford BioMedica received a rating downgrade due to execution risk and programme delays.

1 report, 1 independent Updated Aug 18

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Oxford BioMedica Deutsche Bank

Keep exploring

The entities involved

Oxford BioMedica
bioTech Company
- Oxford BioMedica will leverage Veeva Quality Cloud to drive quality transformation across its global network.Wed 12:19
Deutsche Bank
German global banking and financial services company
- Geopolitical risk adds to UK fiscal pressures as renewed fighting drives up oil prices, prompting economists to analyze market impacts.Mon 15:09
- Bank of America upgraded a rating to buy and suggested a potential equity stake in a Caribbean resort chain, supported by Deutsche Bank.Mon 13:32

Coverage

Newest first; wire copies grouped

Aug 18proactiveinvestors.co.uk